A study analyzing hepatectomy outcomes identified grade A post-hepatectomy liver failure (PHLF) as a distinct entity. Although mortality rates were similar between patients with grade A PHLF and those without, the former exhibited notably inferior postoperative outcomes, including increased morbidity, reoperation, nonoperative intervention, longer hospital stays, and higher readmission rates. Journal Article by Vitello DJ, […]

The utilization of neoadjuvant therapy (nat) for pancreatic cancer varied widely among the United States, Canada, Germany, the Netherlands, and Sweden. However, the overall use of nat increased by 26% from 2018 to 2020. Nat was associated with improved short-term outcomes, including reduced rates of serious morbidity, pancreatic fistulae, and reoperations, as well as increased […]

Patients with resectable pancreatic body or tail cancer who have splenic vein (SPV) involvement, particularly radiological SPV encasement, experience significantly worse overall survival (OS) and recurrence-free survival (RFS). Independent poor prognostic factors include higher pre-operative carcinoembryonic antigen levels, larger tumor size, pathological SPV invasion, and non-completion of adjuvant therapy. Multidetector-row computed tomography shows relatively high […]

Patient-controlled epidural analgesia (PCEA) did not significantly improve postoperative pain during ambulation compared to intravenous patient-controlled analgesia (IV PCA) following open hepatectomy. There was a small difference in pain scores on postoperative day 2, but it did not meet the pre-specified definition of clinical significance. PCEA was safe with a low incidence of epidural failure […]

Researchers developed and validated a new clinically relevant endpoint, Pancreatic Surgery Composite Endpoint (PACE), for pancreatic surgery. PACE incorporates postoperative pancreatic fistula, post-pancreatectomy hemorrhage, reoperation, and reinterventions. It demonstrated high predictive value for prolonged length of hospital stay (LOS) and mortality in both the development and validation cohorts. PACE allowed for significant reduction in sample […]

Researchers identified benchmark values for hepatectomy in intrahepatic cholangiocarcinoma (ICC) across international institutions. Out of 1,193 patients, 600 (50.3%) were included in the benchmark group. The benchmark values encompassed criteria such as lymph node retrieval, blood loss, transfusion rate, operative time, achievement rates for postoperative outcomes, resection margin, complications, mortality, and hospital stay. Establishing these […]

The study compared the outcomes of patients with middle-third cholangiocarcinoma who underwent modified pancreaticoduodenectomy (MPD) or hepatopancreaticoduodenectomy (HPD). The MPD group exhibited advantages such as shorter operation time, less blood loss, and fewer complications compared to the HPD group. Overall survival rates did not significantly differ between the groups. The study identified positive surgical margins […]

A proposed model called the aMAP score was evaluated for its ability to predict long-term outcomes in patients undergoing resection for hepatocellular carcinoma (HCC). The results showed that a high aMAP score was associated with poorer 5-year overall survival (OS) rates compared to a low aMAP score. The aMAP score was also found to be […]

Researchers conducted a study to investigate resection to exploration ratios (RER) and outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). The overall RER was found to be 89.7%, with higher ratios observed in upfront explorations compared to post-neoadjuvant explorations. The primary reasons for uncompleted resection were occult metastases in presumed resectable/borderline resectable disease and local […]

A study found that combining an oncolytic virus with CD19-Chimeric Antigen Receptor-T (CAR-T) cells was effective in treating pancreatic cancer. The engineered virus successfully infected and expressed CD19 on tumor cells, leading to an increased immune response and cell killing when co-cultured with CD19-CAR-T cells. In combination therapy, the virus and CAR-T cells significantly reduced […]